Singapore, Nov. 20 -- China-based Innogen Pharmaceuticals has entered into an exclusive licensing and commercialisation agreement with Arcera Life Sciences for the development and commercialisation of its internally developed innovative product Efsubaglutide Alfa, in international markets.

The collaboration represents an important milestone in the international development of Efsubaglutide Alfa and a significant step forward in Innogen's global expansion strategy. It also highlights the potential for China-originated innovation to move beyond domestic commercialization and reach international markets.

Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries within Africa, Eastern Europe, Latin...